目的 观察扶正消瘤方抗脑胶质瘤的药效及其可能作用机制。方法 采用Wistar大鼠脑右侧尾状核原位接种C6脑胶质瘤细胞建立大鼠脑胶质瘤原位移植模型, 给药组ig给予扶正消瘤方, 连续14 d。末次给药后取血, 测定全血黏度及血浆黏度, 检测血清免疫球蛋白(IgG、IgA、IgM)、肿瘤坏死因子α(TNF-α)、白细胞介素-2(IL-2)、γ干扰素(IFN-γ)水平;取血后处死大鼠, 取脑, 称质量, 计算脑指数;测定肿瘤长、短径, 计算肿瘤体积及抑瘤率;测定肿瘤组织中血管内皮生长因子(VEGF)、前列腺素E₂(PGE₂)、胰岛素样生长因子-1(IGF-1)水平。结果 扶正消瘤方(1.2、2.4、3.6 g/kg)均对脑胶质瘤大鼠肿瘤体积有抑制作用;能不同程度降低肿瘤组织中IGF-1、PGE₂、VEGF及血清IgG水平, 升高血清IgA、IgM、TNF-α、IL-2、IFN-γ水平;降低低切变率下的全血黏度(P < 0.05、0.01)。结论 扶正消瘤方对C6脑胶质瘤具有明显的抑制作用, 其作用机制可能为抑制肿瘤血管新生、抑制肿瘤细胞增殖、增强机体免疫功能和降低血液黏度。

Objective To observe the inhibitory effect of Fuzheng Xiaoliu Decoction (FXD) on cerebral glioma. Methods Rat glioma orthotopic transplantation model was established by inoculating C6 glioma cells to brain right caudate nucleus in situ of Wistar rats, and the rats in treatment group were ig administered with FXD for consecutive 14 d. After the last administration, blood was taken to measure whole blood viscosity and plasma viscosity, serum immunoglobulin (IgG, IgA, and IgM), tumor necrosis factor-α (TNF-α), interleukin-2 (IL-2), and interferon-γ (IFN-γ) levels; All rats were sacrificed after last administration to collect whole blood; The brain was taken and weighed, brain index was calculated, tumor length and short diameters were measured, and tumor volume and inhibitory rate were calculated; The tumor tissue was taken, vascular endothelial growth factor (VEGF) and prostaglandin E₂ (PGE₂), insulin-like growth factor-1 (IGF-1) levels were determined. Results All three doses (1.2, 2.4, and 3.6 g/kg) of FXD could inhibit rat glioma tumor volume. It could reduce the contents of IGF-1, PGE₂, VEGF in tumor tissue and serum IgG, elevated the level of serum IgA, IgM, TNF-α, IL-2, and IFN-γ to varying degrees. FXD (3.6 g/kg) can reduce whole blood viscosity at low shear (P < 0.05, 0.01). Conclusion FXD has significant antitumor effect on C6 glioma, and the mechanism of antitumor effect may be the inhibition of tumor angiogenesis and tumor cell proliferation, enhancing immune response, and reducing blood viscosity.

浙江省重大科技专项(优先主题)社会发展项目(2008C13038-2);浙江省卫生高层次创新人才培养工程项目(浙卫发［2010]190号)